Business
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF
Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, and Qureight Ltd, a Core Imaging Laboratory developing deep-learning image analytics, today announced a collaboration for the integration of Qureight's deep-learning platform into Rein's planned Phase 2 trial of its lead asset LTI-03, a novel, multi-pathway, Caveolin-1-related peptide
About this update from Rein Therapeutics, Inc.
[{"type":"text","content":"AUSTIN, Texas, May 1, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, and Qureight Ltd, a Core Imaging Laboratory developing deep-learning image analytics, today announced a collaboration for the integration of Qureight's deep-learning platform into Rein's planned Phase 2 trial of its lead asset LTI-03, a novel, multi-pathway, Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis (IPF).","length":620,"tagName":"p"},{"type":"image","alt":"Rein Logo (PRNewsfoto/Rein Therapeutics, Inc.)","displaySize":"","headline":null,"caption":"Rein Logo (PRNewsfoto/Rein Therapeutics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":226,"url":"https://media.zenfs.com/en/prnewswire.com/21d12d0173749cab9897840a84c884b9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lUNLcp9yz5L5abyqs4rZrg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5ODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/21d12d0173749cab9897840a84c884b9","width":400,"height":226}},"href":"https://mma.prnewswire.com/media/2595086/Rein_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Rein previously announced positive topline results from Cohort 2 (5 mg BID) of the Phase 1b clinical trial of LTI-03 in IPF, in which a positive trend was observed in seven out of eight biomarkers evaluated, with five biomarkers demonstrating dose-dependent effects and four biomarkers achieving statistical significance in the combined Cohort 1 and Cohort 2 data set.","length":368,"tagName":"p"},{"type":"text","content":"The Phase 2 clinical trial of LTI-03 will evaluate the safety and tolerability of LTI-03 in patients with IPF, as well as its activity across multiple biomarkers, and measure lung function and the potential for healthy tissue regeneration. In the trial, Qureight will provide full end-to-end imaging core lab services, including site qualification, data handling, quality control and deep-learning AI image analysis. Qureight's deep-learning platform will be used to analyze lung imaging data and identify potential correlations between any volumetric changes within the lungs of IPF patients and LT...